Quarterly ResultMay 6, 2026, 08:17 AM
Taysha Gene Therapies Reaffirms TSHA-102 BLA Pathway; Q1 Net Loss $42.4M
AI Summary
Taysha Gene Therapies reported its first quarter 2026 financial results and provided a corporate update, highlighting significant progress in its TSHA-102 program for Rett syndrome. The company reaffirmed FDA alignment on the BLA pathway for TSHA-102, including the potential for approval based on a six-month interim analysis of the REVEAL pivotal trial. While clinical development is advancing positively with dosing on track and a favorable tolerability profile, the company experienced increased research and development expenses and a higher net loss for the quarter.
Key Highlights
- Reaffirmed FDA alignment on TSHA-102 BLA pathway, including potential approval based on 6-month interim analysis from REVEAL pivotal trial.
- On track to complete dosing in REVEAL pivotal trial and ASPIRE trial in Q2 2026.
- TSHA-102 maintained favorable tolerability with no treatment-related SAEs or DLTs as of May 2026 data cutoff.
- Initiated BLA-enabling PPQ campaign for TSHA-102 in April 2026, expected completion Q4 2026.
- Research and development expenses increased to $33.8 million for Q1 2026 from $15.6 million in Q1 2025.
- General and administrative expenses rose to $9.7 million for Q1 2026 from $8.2 million in Q1 2025.
- Net loss for Q1 2026 was $42.4 million, or $0.12 per share, compared to $21.5 million, or $0.08 per share, in Q1 2025.
- Cash and cash equivalents totaled $276.6 million as of March 31, 2026, sufficient to fund operations into 2028.